Grandaxin (Tofisopam)

Grandaxin (tofisopam) is primarily prescribed for the relief of anxiety in adult patients.

• Short‑term treatment of generalized anxiety disorder.
• Adjunctive therapy for anxiety associated with depressive disorders.
• Management of situational anxiety such as performance or exam stress.
• Use in patients who require anxiolysis without marked sedation or muscle relaxation.
• Temporary relief of anxiety symptoms during withdrawal from other anxiolytics.
• Supportive treatment for anxiety in patients with a history of substance misuse where sedative effects are undesirable.

The safety profile of Grandaxin reflects its selective anxiolytic action, with most patients experiencing mild, transient effects. These effects are generally dose‑related and resolve after discontinuation or dose adjustment.

Common

• Dizziness or light‑headed feeling.
• Mild headache.
• Nausea or gastrointestinal discomfort.
• Transient fatigue or drowsiness.
• Difficulty concentrating.
• Dry mouth.

Serious

• Allergic skin reactions such as rash or urticaria.
• Signs of hepatic dysfunction, including jaundice or elevated liver enzymes.
• Mood changes such as depression or suicidal thoughts.
• Severe hypotension or fainting.

Clinicians should evaluate several factors before prescribing Grandaxin to ensure safe and appropriate use.

• Assess liver function, as tofisopam is metabolized hepatically.
• Use caution in patients with a history of substance abuse or dependence.
• Evaluate renal function in elderly patients, although renal excretion is minimal.
• Avoid use during pregnancy and lactation unless benefits outweigh risks, due to limited safety data.
• Monitor for emergence of depressive symptoms or suicidal ideation.
• Do not combine with other central nervous system depressants without medical supervision.

Grandaxin may interact with other medications that affect the central nervous system or hepatic metabolism.

Avoid

• Concomitant use with other benzodiazepines or barbiturates, which can increase sedation and respiratory depression.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) that may raise tofisopam plasma levels.
• Monoamine oxidase inhibitors (MAOIs), as combined use may lead to unpredictable CNS effects.

Use with caution

• Alcohol, because combined use can enhance drowsiness.
• Antidepressants, particularly SSRIs or SNRIs, due to potential additive effects on mood.
• Antihistamines or antipsychotics, which may increase central nervous system depression.